



Eisai Co., Ltd.

4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 , Japan

Phone: 03- 3817-5120

Fax: 03- 3811-3077

Eisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their families to enhance the quality of life.

FOR IMMEDIATE RELEASE

No. 08-33

May 16, 2008

Eisai Co., Ltd.

Eisai Presents 16 Papers Accepted for ASCO Annual Meeting Reporting the Latest Results from its Oncology Research

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) announced today that results from 16 clinical data abstracts about compounds in the company’s oncology pipeline and preclinical oncology research have been accepted for presentation at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 30 to June 3, 2008.

A wide variety of abstracts on Eisai marketed products and investigational compounds will showcase research focused on metastatic breast cancer, lung cancer, ovarian cancer, brain cancer, mesothelioma, pancreatic cancer, myelodysplastic syndromes and other types of cancer, as well as supportive care to aid those currently undergoing treatment for cancer.

“Eisai’s commitment to oncology is clearly translating into substantial results in a growing pipeline,” said Haruo Naito. “Eisai’s focus on becoming a global leader in oncology reflects our human health care mission to satisfy unmet medical needs and increase benefits to patients and their families.”

The following Eisai abstracts are accepted for presentation at this year’s ASCO meeting.

Product	Abstract Details	Location Details
MORAb-003 (farletuzumab) Abstract No: 5500	Exploratory Phase II Efficacy Study of MORAb-003, a Monoclonal Antibody against Folate Receptor Alpha, in Platinum-Sensitive Ovarian Cancer in First Relapse <i>Oral Presentation</i>	June 1, 2008 4:30-4:45 p.m. Location: S406 (Vista Room)
E7080 Abstract No: 3526	A phase I study of E7080 in patients with advanced malignancies Poster 3 Awarded a Foundation Merit Award	May 31, 2008 8:00 a.m.-12:00 p.m. Location: W375E Lobby <i>Poster discussion</i> 12:00-1:00 p.m. Location: W375A
E7080 Abstract No: 3527	Phase I dose escalation study and biomarker analysis of E7080 in patients with advanced solid tumors Poster 4	May 31, 2008 8:00 a.m.-12:00 p.m. Location: W375E Lobby <i>Poster discussion</i> 12:00-1:00 p.m. Location: W375A

Cutaneous T-cell Lymphoma Abstract No: 8551	(Integrated analysis of three large Phase III trials in CTCL) Poster 45A	May 31, 2008 8:00 a.m.-12:00 p.m. Location: S Hall A1
MORAb-003 (farletuzumab) Abstract No: 5517	A Phase I Study of MORAb-003, a Humanized Monoclonal Antibody Against Folate Receptor Alpha, in Advanced Epithelial Ovarian Cancer Poster 7	May 31, 2008 2:00-6:00 p.m. Location: S403 <i>Poster discussion</i> 5:00-6:00 p.m. Location: S406 (Vista Room)
ALOXI® (palonosetron HCl) Abstract No: 9617	Palonosetron (PALO) for Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High-dose Melphalan Prior to Stem Cell Transplant Poster 46B	May 31, 2008 2:00-6:00 p.m. Location: S Hall A1
GCP II Inhibitor Abstract No: 9558	Glutamate Carboxypeptidase II Inhibition in Rat Models of Chemotherapy-induced Peripheral Neurotoxicity Poster 37A	May 31, 2008 2:00-6:00 p.m. Location: S Hall A1
E7820 Abstract No: 3568	A phase I study of E7820 in combination with cetuximab in patients (pts) with advanced solid tumors Poster 24G	June 1, 2008 2:00-6:00 p.m. Location: S Hall A1
MORAb-009 Abstract No: 3578	A Phase I Study of MORAb-009, a Monoclonal Antibody against Mesothelin, in Mesothelioma, Pancreatic, and Ovarian Cancer Poster 27C	June 1, 2008 2:00-6:00 p.m. Location: S Hall A1
Eribulin Mesylate (E7389) Abstract No: 1084	Phase II Study of Eribulin Mesylate (E7389) in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracycline, Taxane, and Capecitabine Therapy Poster 38A	June 2, 2008 2:00-6:00 p.m. Location: S Hall A1
Advanced Breast Cancer Abstract No: 1064	Oncologist and Patient Roles in Assessing Current and Future Treatment for Metastatic Breast Cancer: Results of an Observational Linguistic study Poster 32B	June 2, 2008 2:00-6:00 p.m. Location: S Hall A1
DACOGEN® (decitabine) Abstract No: 7032	A Multicenter Phase II Trial of the Decitabine Alternative 5-day Dosing Regimen: Analysis of Efficacy in Various Subgroups of Patients with Myelodysplastic Syndromes Poster 21	June 2, 2008 2:00-6:00 p.m. Location: E450A <i>Poster discussion</i> 5:00-6:00 p.m. Location: E354A
DACOGEN® (decitabine) Abstract No: 7030	Cytogenetic Responses to a 5-Day Dosing Schedule of Decitabine in Patients with Myelodysplastic Syndromes Poster 19	June 2, 2008 2:00-6:00 p.m. Location: E450A <i>Poster discussion</i> 5:00-6:00 p.m. Location: E354A

ALOXI [®] (palonosetron HCl)	Palonosetron (PALO) versus granisetron (GRAN), both combined with dexamethasone (DEX) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with cisplatin- or anthracycline plus cyclophosphamide-based regimens: Results of a Phase III trial in Japanese patients (This study was conducted by Taiho Pharmaceutical Co., Ltd. in Japan with support from Helsinn Healthcare SA. Taiho owns the marketing rights in Japan for palonosetron HCl.)	Accepted for publication only.
ALOXI [®] (palonosetron HCl)	Palonosetron (PALO), administered orally or intravenously (IV), plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV)	Accepted for publication only.
GLIADEL [®] Wafer (polifeprosan 20 with carmustine implant)	Treatment of Adults with Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma with Surgery, Gliadel Wafers and Limited Field Radiation Plus Concomitant Temozolomide Followed by Adjuvant Temozolomide	Accepted for publication only.

Eisai began its oncology research program in 1987, discovering several small molecules that are in development as chemotherapeutic agents. In addition to its in-house oncology research and development (R&D) program, Eisai made three strategic acquisitions to establish a solid business infrastructure and enter the U.S. oncology market.

In October 2006, Eisai acquired four products mainly for the treatment of cutaneous T-cell lymphoma, as well as an oncology specialty sales force, from Ligand Pharmaceuticals. This provided Eisai with an initial commercial infrastructure for oncology products. The acquisition of Morphotek, Inc. in April 2007 added important antibody technology and an antibody pipeline. In January 2008, Eisai acquired MGI PHARMA, INC., an oncology and acute care-focused company, to broaden its R&D and commercial capabilities, pipeline and product portfolio in oncology and supportive care.

Eisai is committed to addressing the unmet medical needs of patients with cancer and deliver novel treatment options that create hope with them.

Contacts:
Corporate Communications Department
Eisai Co., Ltd.
81-3-3817-5120